Trend Engineering biology takes off as AI enters biomanufacturing and gene editing advances

Summary

The plan observes that AI is now being applied in earnest to biomanufacturing and drug design. Combined with increasingly sophisticated gene editing, this is bringing engineering biology into full swing. It records that a CRISPR-based gene-editing therapy was commercialized in May 2025 and that fourth-generation prime editing is forecast to reach commercial use around 2030. The foresight comparison in the plan likewise shows several institutions naming advanced biotechnology items such as gene-editing therapies, embryo gene prediction, gene restoration and synthetic biology. The plan treats engineering biology as one of the fields where frontier science is moving quickly into industry.